Healthcare entity
Every one of those 1 sits in a single category, market-trends. BIMZELX is most often covered alongside AbbVie, which appears in 1 of these 1 story. At 6, the average consequence score sits above the same-window beat average of 5.8.
Last mentioned: Mar 24, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. BIMZELX is most often covered alongside AbbVie, which appears in 1 of these 1 story. At 6, the average consequence score sits above the same-window beat average of 5.8. Each story carries 2 original sources on average, compared with 2.4 for the broader beat in this window. We currently track 1 Healthcare story that mention BIMZELX, all published on March 24, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 29 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering BIMZELX. Shared-story counts are live from our verified record — not editorial picks.
Belgian biopharma giant UCB has announced a massive $2 billion investment to establish a new manufacturing plant in suburban Atlanta, creating 330 high-skilled jobs. The move strengthens UCB's U.S. footprint as it scales production for its high-growth immunology portfolio.
BIMZELX is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
